Diabetic Foot Ulcer Biologics Market Report 2026

The diabetic foot ulcer biologics market size has grown strongly in recent years. It will grow from $1.93 billion in 2025 to $2.09 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to limited availability of advanced biologics, reliance on conventional wound care treatments, rising prevalence of diabetes-related foot ulcers, increasing hospital and clinic adoption, lack of standardized treatment protocols.

The diabetic foot ulcer biologics market size is expected to see strong growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to technological advancements in stem cell and gene therapy, growing investment in tissue engineering research, increasing adoption of autologous and allogeneic cell-based biologics, expansion of long-term care and ambulatory surgical centers, rising awareness of personalized wound care solutions. Major trends in the forecast period include increasing adoption of stem cell and gene therapies, rising use of collagen-based biologics for wound healing, expansion of skin substitutes in diabetic foot ulcer management, integration of advanced tissue engineering techniques, growing focus on personalized and targeted biologics treatments.

The increasing prevalence of diabetes is anticipated to drive the growth of the diabetic foot ulcer biologics market in the coming years. Diabetes is a chronic condition marked by elevated blood glucose levels resulting from the body’s inability to produce sufficient insulin or effectively utilize it. The rise in diabetes prevalence is largely attributed to sedentary lifestyles, which is increasing the need for long-term care solutions that manage blood sugar levels efficiently while minimizing daily lifestyle disruptions. Diabetic foot ulcer biologics play a critical role in diabetes care by accelerating wound healing, preventing infections, and reducing complications associated with chronic foot ulcers. For instance, in April 2025, according to the International Diabetes Federation (IDF) Atlas, a Belgium-based non-profit organization, type 1 diabetes affected approximately 9.5 million of the 589 million adults living with diabetes in 2024, and the total number of adults with diabetes is projected to increase to 853 million by 2050. Therefore, the growing prevalence of diabetes is contributing to the expansion of the diabetic foot ulcer biologics market.

Major companies operating in the diabetic foot ulcer biologics market are prioritizing research and development of advanced biologic therapies, such as placental-derived allografts, to improve wound healing, lower complication rates, and enhance patient outcomes in the management of chronic foot ulcers. Placental-derived allografts are biological tissue grafts sourced from donated human placental tissues, including the amnion or chorion, and are used clinically to promote tissue regeneration, reduce inflammation, and support effective healing. For instance, in January 2025, BioStem Technologies Inc., a US-based pharmaceutical company, initiated a clinical trial evaluating its BioREtain technology combined with Vendaje for the treatment of diabetic foot ulcers. The study compares Vendaje plus standard care with standard care alone to assess its effectiveness in healing non-healing diabetic foot ulcers and includes a follow-up phase to examine the long-term durability and stability of healed wounds, aiming to ensure sustained treatment success and reduce the risk of ulcer recurrence.

In March 2024, BiomX Inc., a US-based biotechnology company specializing in phage therapy, acquired Adaptive Phage Therapeutics Inc. for an undisclosed amount. Through this acquisition, BiomX seeks to establish a leading position in phage-based therapeutics by integrating complementary platforms and strengthening its development pipeline, which includes two Phase 2 programs targeting chronic pulmonary infections in cystic fibrosis and diabetic foot osteomyelitis. Adaptive Phage Therapeutics Inc. is a US-based clinical-stage biotechnology company focused on developing personalized phage therapies for serious bacterial infections.

Major companies operating in the diabetic foot ulcer biologics market are Smith & Nephew plc, Integra LifeSciences Holdings Corp., Organogenesis Holdings Inc., MIMEDX Group Inc., LifeNet Health, Aroa Biosurgery, Tissue Regenix Group plc, Stempeutics Research, ACell Inc.,

North America was the largest region in the diabetic foot ulcer biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic foot ulcer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic foot ulcer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the diabetic foot ulcer biologics market by increasing costs for imported biologics materials, cell culture reagents, and advanced tissue engineering components. Segments like cell-based biologics and collagen-based therapies are particularly impacted, with regions such as North America and Asia-Pacific facing higher import duties. This has resulted in elevated production costs and potential delays in product availability. On the positive side, tariffs encourage domestic production, local sourcing of biologic materials, and innovation in cost-effective biologic therapies.

The diabetic foot ulcer biologics market research report is one of a series of new reports that provides diabetic foot ulcer biologics market statistics, including diabetic foot ulcer biologics industry global market size, regional shares, competitors with a diabetic foot ulcer biologics market share, detailed diabetic foot ulcer biologics market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic foot ulcer biologics industry. This diabetic foot ulcer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic foot ulcer biologics are advanced therapeutic products derived from living cells, tissues, or biological materials that are designed to support wound healing and tissue regeneration in diabetic foot ulcers. These biologics enhance the body’s natural repair mechanisms by supplying essential growth factors, extracellular matrices, and cellular components, thereby accelerating healing and reducing complications associated with chronic diabetic wounds.

The main types of diabetic foot ulcer biologics include growth factors, skin substitutes, collagen-based biologics, and cell-based biologics. Growth factors are natural or synthetic agents that stimulate cell proliferation, differentiation, and tissue regeneration to aid the healing process. Key indications for these biologics include neuro-ischemic ulcers, neuropathic diabetic foot ulcers, and ischemic diabetic foot ulcers. The technologies involved include gene therapy, stem cell therapy, and tissue engineering, and these products are used across various end-user settings such as hospitals, clinics, ambulatory surgical centers, long-term care facilities, and others.

The diabetic foot ulcer biologics market consists of revenues earned by entities by providing services such as wound care management services, personalized treatment planning, post-operative care and follow-up, telemedicine and remote monitoring, and clinical trial and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic foot ulcer biologics market also includes sales of bioreactors and cell culture systems, tissue processing and preservation devices, wound dressing application tools, and automated cell sorting and separation machines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.